Abstract:PINK1 and Parkin mutations lead to the early onset of Parkinson’s disease. PINK1-mediated phosphorylation of its substrates such as ubiquitin (Ub), ubiquitin-like protein (NEDD8), and ubiquitin-like (Ubl) domain of Parkin activate autoinhibited Parkin E3 ligase. The mechanism of various phospho-Ubls binding on Parkin and conformational changes leading to Parkin activation remain elusive. Herein, we determine the first crystal structure of human Parkin E3 ligase bound with phospho (p)-NEDD8, which shows that NEDD8 has evolved over Ub to bind and activate Parkin more robustly. X-ray crystal structures and supporting biophysical/biochemical data reveal specific recognition and underlying mechanisms of pUb/pNEDD8 and pUbl domain binding to the RING1 and RING0 domains, respectively. This new data also shows that pUb/pNEDD8 binding in the RING1 pocket causes allosteric conformational changes in Parkin’s catalytic domain (RING2), leading to Parkin activation. Furthermore, Parkinson’s disease mutation K211N in the RING0 domain of Parkin was believed to lose its activation due to loss of interaction with pUb. However, our data reveal allosteric conformational changes due to N211 that lock RING2 with RING0 to inhibit Parkin K211N activity without disrupting pNEDD8/pUb binding. This study would aid the design of small-molecule Parkin activators for the treatment of Parkinson’s disease.

What problem does this paper attempt to address?

The issues this paper attempts to address are: 1. **Clarify the specific interaction mechanism between phosphorylated ubiquitin-like proteins (p-Ubls) and Parkin**: Researchers aim to reveal the specific mechanism by which p-Ubls bind and activate Parkin by analyzing the crystal structure of the human Parkin E3 ligase in complex with phosphorylated NEDD8 (p-NEDD8). 2. **Explain the effects of different phosphorylated ubiquitin-like proteins on Parkin activation**: Researchers compare the different effects of p-Ub and p-NEDD8 on Parkin activation through quantitative ubiquitination experiments to understand why p-NEDD8 activates Parkin more effectively than p-Ub. 3. **Explore the specific recognition mechanism of Parkin's RING0 and RING1 pockets for different activators**: Researchers attempt to elucidate how Parkin's two pockets (RING0 and RING1) specifically recognize different phosphorylated activators (such as p-Ubl, p-Ub, and p-NEDD8) and the specific molecular mechanisms involved in these recognition processes. 4. **Analyze the impact of the Parkin disease mutation K211N**: Researchers investigate the effect of the K211N mutation on Parkin activity, particularly whether this mutation leads to the loss of Parkin activity by affecting the binding of p-Ub or p-NEDD8, and the underlying molecular mechanisms. 5. **Provide a theoretical basis for designing small molecule activators of Parkin**: Through the above studies, researchers hope to provide detailed structural and functional information for developing small molecule activators targeting Parkin, thereby offering new strategies for treating Parkinson's disease.

Specific interactions with phospho-Ubls and allosteric conformational changes regulate the E3 ligase activity of Parkin